Vanguard Global Advisers’s Corcept Therapeutics CORT Stock Holding History
Bought
Maintained
Sold
Other funds holding CORT
Vanguard Global Advisers's CORT Position: Q3 2026 in Review
Vanguard Global Advisers increased its Corcept Therapeutics (CORT) stake by 11% in Q3 2026, buying an estimated $452K and bringing the position to 41,623 shares worth $4.8M. The position accounts for ﹤0.01% of the portfolio, ranked #806.
Vanguard Global Advisers first reported a position in CORT in Q1 2026 and has held it in 3 quarters since. 463 funds tracked by Wall St. Rank hold CORT as of Q3 2026.
- Vanguard Global Advisers held 41,623 shares of Corcept Therapeutics worth $4.8M as of Q3 2026.
- Vanguard Global Advisers bought 4,206 Corcept Therapeutics shares in Q3 2026, an estimated $452K.
- Corcept Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #806 holding.
- Vanguard Global Advisers first reported a position in Corcept Therapeutics in Q1 2026 and has held it in 3 quarters since.
- 463 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.